DaVita Inc. $DVA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 19.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,075 shares of the company’s stock after selling 8,909 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.05% of DaVita worth $4,926,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of DVA. KBC Group NV boosted its holdings in shares of DaVita by 38.7% in the 2nd quarter. KBC Group NV now owns 374,749 shares of the company’s stock valued at $53,383,000 after purchasing an additional 104,554 shares during the last quarter. Nordea Investment Management AB grew its position in shares of DaVita by 1.8% during the third quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock worth $37,864,000 after buying an additional 5,193 shares in the last quarter. Man Group plc increased its position in shares of DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after buying an additional 150,318 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC raised its position in shares of DaVita by 49.1% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock valued at $36,730,000 after acquiring an additional 84,859 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DVA shares. Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Barclays reduced their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a report on Thursday, October 30th. TD Cowen restated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $145.60.

DaVita Trading Down 0.4%

Shares of NYSE DVA opened at $107.68 on Tuesday. The company has a 50-day moving average of $114.38 and a two-hundred day moving average of $126.07. The company has a market cap of $7.60 billion, a PE ratio of 11.09, a P/E/G ratio of 0.67 and a beta of 0.99. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. During the same period last year, the company earned $2.59 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.